Remove 2010 Remove Efficiency Remove Ethics Remove Price
article thumbnail

Lessons from the Best Global Brands 2010: Building trust and.

Strategy Driven

StrategyDriven effective executives, efficient employees Home About The StrategyDriven Organization Our Company Our Contributors Karen K. While the rules may be shifting, the long-term sustainable advantage gained by building a strong brand – a brand that builds stability, trust, loyalty, and drives a premium price – remains consistent.

Brand 66
article thumbnail

Leadership Self Examination | N2Growth Blog

N2Growth Blog

They will not compromise their value system and personal ethics for temporary gain. They are voracious learners always looking for better methods, different approaches, enhanced efficiencies, better technology and increased velocity. But Everything has a price, there is no smoke without fire!!!! Want to find out? Our Freedom.

Blog 366
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ethical Consumerism Isn’t Dead, It Just Needs Better Marketing

Harvard Business Review

Ethical consumerism is the broad label for companies providing products that appeal to people’s best selves (for example, fair trade coffee or a purchase that includes a donation to a charitable cause). This pessimistic stance stems primarily from the lower sales of ethical brands. We cannot shop our way to a better world.”

Ethics 8
article thumbnail

Definition of Leadership | N2Growth Blog

N2Growth Blog

But because true leaders are motivated by loving concern than a desire for personal glory, they are willing to pay the price.&# - Eugene B. The Ten Commandments and the Sermon on the Mount are all the ethical code anybody needs.&# - Harry S. Copyright/Legal Privacy Resources Sitemap N2Growth Blog © Copyright 2010 N2Growth.

article thumbnail

How Pharma Can Fix Its Reputation and Its Business at the Same Time

Harvard Business Review

It’s a fact that the current business model of pharma companies is not working efficiently. The estimated return on these (fewer) products has itself declined substantially since 2010, from 10.1% This represents a disquieting trend for companies whose profit growth heavily depends on price increases.